Nelonicline

DB19040InvestigationalSmall molecule

Nelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-7
Curator reviewed
Formula / weight: C₁₇H₁₉N₃OS · 313.42 g/mol (avg)
Also known as: 2-((3r,4s,5s,7s)-1-azaadamantan-4-yloxy)-5-phenyl-1,3,4-thiadiazole, rel-
Code names: ABT-126

Resolves to

Compound

UNIIWX8LOM674DCAS1026134-63-3

Structure

InChIKeyQZDCYUCETTWCMO-WTGKZIDZSA-NSMILESC1[C@H]2C[C@@H]3CN(C2)C[C@H]1[C@@H]3OC1=NN=C(S1)C1=CC=CC=C1

Targets

P36544CHRNA7

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nelonicline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account